Bli medlem
Bli medlem

Du är här


Senzime: "OnZurf probe" nominated for the Athena Award 2015

Translation of press release published Monday November 2, 2015

Uppsala, November 2, 2015. Senzime's (publ) OnZurf probe is nominated
for Sweden's largest prize for outstanding achievements in clinical
research. The Athena Award recognizes research done in collaboration
between healthcare, academia and industry, and the research shall be
of benefit to patients and healthcare.

OnZurf probe originates from Umeå University where Pernilla
Abrahamsson during her research studies discovered that it is
possible to measure metabolic changes from the surface of an organ
instead of having to puncture it. The discovery means less risk of
complications and thus expanded the use of microdialysis technique.

"Healthcare today has great need for easier and faster diagnosis of
seriously ill patients to reduce the risk of complications and thus
be able to avoid long periods of care and high costs. OnZurf probe
creates good conditions for an easier and faster diagnosis, which
makes earlier identification of complications such as after an
operation possible. This leads to more effective treatment, reduced
suffering, increased survival and lower healthcare costs, "says
Pernilla Abrahamsson, Product and Business Development Manager at
Senzime AB.

The nomination procedure was conducted in two steps. In the first step
the jury was given nominations with a brief motivation. In the second
step, the jury made a selection of nominees which then submitted a
detailed description of their research and results.

Examples of projects that can be awarded is development and
improvement of diagnosis, treatment or prevention. It can also
involve new methods, technologies and products which improve health
care. One requirement is that the research has been done in close
collaboration between health care, academia and industry. The award
is worth 150,000 SEK and the principals of the price are Vinnova and
Dagens Medicin.

For further information, please contact:

Lena Söderström, CEO of Senzime AB
Tel: +46 708-16 39 12, email:

About Senzime

Senzime develops and markets analytical instruments and related
disposable products, enabling automated, continuous monitoring of
vital substances including glucose (sugar), in biological fluids.
Senzime has two platforms for continuously monitoring glucose and
lactate - BioSenz in biotech environment and CliniSenz for continuous
patient-monitoring. Via microdialysis in tissue or blood Senzime
offers a complete system enabling continuous monitoring which is
critical to detect post- surgery complications. The company's share
is listed on Aktietorget since 2008.

About OnZurf

OnZurf, a new generation of microdialysis catheters that allow for
organ specific monitoring of, for example, bowel, liver and heart
after surgery. Microdialysis is a technology that was originally
developed at the Karolinska Institute in the 1970's and is today
validated in over 15,000 scientific studies.


Författare ATORG

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.